Akebia Therapeutics, Inc. announced that it will present data at the American Society of Nephrology Kidney Week 2023 (ASN Kidney Week), which will take place at the Pennsylvania Convention Center in Philadelphia from November 2-5, 2023. Akebia-supported posters will be presented at ASN Kidney Week on November 2, 2023, from 10:00 a.m. - 12:00 p.m.EST. ASN Kidney Week attendees can also visit Akebia at Booth #2515 in the Exhibit Hall.

Notably, Akebia will present a poster with data on alternate dosing for vadadustat, its investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for the treatment of anemia due to chronic kidney disease in adult patients on dialysis.kebia resubmitted a New Drug Application for vadadustat as a daily treatment to the U.S. Food and Drug Administration in late September and expects a Prescription Drug User Fee Act (PDUFA) date to be assigned before the end of October. Safety and Efficacy of Vadadustat Thrice Weekly in Patients with Anemia Due to Dialysis-Dependent Chronic Kidney Disease - Poster Board #: TH-PO983. Randomized Assessment of Auryxia® (ferric citrate) Therapy for In-Center and Home Dialysis Patients - Poster Board #: TH-PO967.

Hospitalizations and RBC Transfusions in Patients with DD-CKD on Auryxia® (ferric citrate) Compared to Other Phosphate Binders - Poster Board #: TH-PO973. Safety and Tolerability of Auryxia® (ferric citrate) in Children with Hyperphosphatemia Related to Chronic Kidney Disease - Poster Board #: INFO12-TH. Decision Tree Model Simulating the Burden of Hyperphosphatemia in U.S. Adult Patients with ESKD on Dialysis - Poster Board #: TH-PO139.